External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ISLS 2023
Roche and Genentech at

ISLS 2023

October 18 - October 21
Zurich, Switzerland
isls2023.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
12:05 PM
Duration 15mins Main Room
IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Adam Yopp, Pierce Chow, Minshan Chen, Ann-Lii Cheng, Ahmed Kaseb, Masatoshi Kudo, Han Chu Lee, Jian Zhou, Lu Wang, Xiaoyu Wen, Jeong Heo, Won Young Tak, Shinichiro Nakamura, Kazushi Numatta, Thomas Uguen, David Hsiehchen, Edward Cha, Stephen P. Hack, Qinshu Lian, Jessica Spahn, Chun Wu, Shukui Qin
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.